SOSV portfolio company Cauldron talked to TechCrunch about their $13.25 million Series A2 round, led by Main Sequence Ventures with participation from Horizons Ventures, NGS Super, and SOSV.
60% of inputs to the global economy could be produced biologically. Cauldron is making that future tangible.
Their “hyper fermentation” technology keeps microbes in a continuously optimized, high-productivity state, unlocking dramatically better performance from existing systems. Even better, it works inside today’s batch fermentation infrastructure with relatively minor retrofits.
Customers bring their own strains; Cauldron fine-tunes the conditions (nutrients, environment, process) to keep them operating at peak output.
Today, they’re focused on fats and proteins, including whey (“a product that can slip directly into existing supply chains”). But that’s just the entry point. Cauldron is rapidly expanding into a much broader set of bio-based products.